Rafael Gonzalez, MD
General Practice · Miami, FLNPI 1487608840
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 8 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 8 manufacturers reported payments, led by Next Science LLC at 40.5% of the total. Reporting peaked in 2024 at $135 and has fallen 73.2% since, to $36 in 2025. That places this record below the midpoint for general practice clinicians in FL, where the typical reported total is $253.
Across 8 payments — averaging $36.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Next Science LLC$118
- Terumo Cardiovascular Systems Corporation$51
- Edwards Lifesciences$34
- 180 Medical, Inc.$20
- Pfizer$19
- Boston Scientific$17
- plus $32 from 2 others
Across 164 payments — averaging $13,233 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Janssen Research & Development, LLC$557K
- Celltrion, Inc.$465K
- Chiesi USA, Inc.$341K
- Avanir Pharmaceuticals, Inc.$325K
- Otsuka Pharmaceutical Development & Commercialization, Inc.$298K
- First Wave Biopharma, Inc.$115K
- plus $70K from 2 others
What the payments were for
- Food & beverage$292100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Next Science LLC | 1 | $118 |
| Terumo Cardiovascular Systems Corporation | 1 | $51 |
| Edwards Lifesciences | 1 | $34 |
| 180 Medical, Inc. | 1 | $20 |
| Pfizer | 1 | $19 |
| Boston Scientific | 1 | $17 |
| Galderma Laboratories, L.p. | 1 | $16 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$292 in reported general payments places this provider in the 50th percentile of 6,901 general practice providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 137 | $78,595 |
| EntrestoSacubitril/Valsartan | 106 | $71,067 |
| Saxagliptin-Metformin ErSaxagliptin Hcl/Metformin Hcl | 180 | $62,993 |
| Pregabalin | 399 | $29,548 |
| Solifenacin Succinate | 137 | $29,311 |
| DapagliflozinDapagliflozin Propanediol | 53 | $26,878 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 313 | $25,948 |
| Dabigatran EtexilateDabigatran Etexilate Mesylate | 180 | $22,935 |
| Tadalafil | 189 | $20,995 |
| Humalog Kwikpen U-100Insulin Lispro | 93 | $17,216 |
| EligardLeuprolide Acetate | 13 | $16,479 |
| Tolterodine Tartrate ErTolterodine Tartrate | 82 | $16,470 |
| Gabapentin | 1,391 | $13,646 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 140 | $12,789 |
| SynthroidLevothyroxine Sodium | 265 | $12,001 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $19 | $78,595137 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 6,901 general practice providers in Florida.
Other general practice in Miami
- Idalia AcostaMiami$99K
- Eddie GomezMiami$59K
- Aladino ValienteMiami$24K
- Viviana WaichMiami$20K
- Libia RiosMiami$15K
- Jose CardonaMiami$15K
- Rosa HuguetMiami$15K
- Robert VogelPalm Beach Gardens$1M
- Bruce OuelletteWest Palm Beach$724K
- Caley CasteleinMiami Beach$586K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.